Skip to main content
SpringerLink
Log in

Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis

  • Review
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Objective

To summarise the evidence of the efficacy and safety of current long-term immunotherapies in patients with myelin oligodendrocyte glycoprotein antibody disease (MOG-AD).

Methods

We performed a sensitive literature search in MEDLINE and EMBASE for selected studies or case series discussing the long-term treatments and outcomes in adult patients with MOG-AD and conducted a qualitative analysis of each therapy.

Results

A total of 33 articles, including 712 patients with MOG-AD, matched our inclusion criteria, and seven kinds of drugs were analysed accordingly. Efficacy was mainly reflected by the change in the annual relapse rate before and after treatment. First, maintenance steroids, azathioprine, mycophenolate mofetil, and rituximab were demonstrated to be effective in multiple studies. However, relapses could still happen after therapy especially under specific circumstances. Second, regular intravenous immunoglobulin G (IVIG) and tocilizumab might be effective. IVIG reduced annual relapse rate and expanded disability status scale in five adult patients, and tocilizumab succeeded in preventing relapse in four refractory patients, though with scant evidence. Finally, multiple sclerosis-disease-modifying therapy seemed ineffective for patients with MOG-AD. As for safety, six patients experienced severe neutropenia during rituximab therapy. No other serious adverse events were reported for these treatments.

Conclusions

Several preventive immunotherapies have been demonstrated to be effective and safe for adult patients with MOG-AD; however, large controlled studies for subgroups with specific manifestations are still needed in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Peschl P, Bradl M, Hoftberger R, Berger T, Reindl M (2017) Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol 8:529. https://doi.org/10.3389/fimmu.2017.00529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Johns TG, Bernard CC (1999) The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72(1):1–9. https://doi.org/10.1046/j.1471-4159.1999.0720001.x

    Article  CAS  PubMed  Google Scholar 

  3. Reindl M, Di Pauli F, Rostasy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455–461. https://doi.org/10.1038/nrneurol.2013.118

    Article  CAS  PubMed  Google Scholar 

  4. Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266(5):1280–1286. https://doi.org/10.1007/s00415-018-9122-2

    Article  Google Scholar 

  5. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B (2016) MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. https://doi.org/10.1186/s12974-016-0718-0

    Article  Google Scholar 

  6. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90(21):e1858–e1869. https://doi.org/10.1212/wnl.0000000000005560

    Article  CAS  PubMed  Google Scholar 

  7. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128–3138. https://doi.org/10.1093/brain/awx276

    Article  PubMed  Google Scholar 

  8. Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89–102. https://doi.org/10.1038/s41582-018-0112-x

    Article  CAS  PubMed  Google Scholar 

  9. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111–e120. https://doi.org/10.1212/wnl.0000000000009758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin B, Mathey G, Laplaud D, Thouvenot E, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett JL, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Jacob A (2020) Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Multiple Scler Relat Disord 44:102251. https://doi.org/10.1016/j.msard.2020.102251

    Article  Google Scholar 

  11. Inan B, Gocmen R, Vural A, Colpak AI, Meinl E, Karabudak R, Tuncer A (2020) Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. Multiple Scler Relat Disord 44:102376. https://doi.org/10.1016/j.msard.2020.102376

    Article  Google Scholar 

  12. Alshamrani F, Alnajashi H, Shosha E, Casserly C, Morrow SA (2020) Case series: myelin oligodendrocyte glycoprotein-immunoglobulin g-related disease spectrum. Front Neurol 11:89. https://doi.org/10.3389/fneur.2020.00089

    Article  PubMed  PubMed Central  Google Scholar 

  13. Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, Zhang W, Li J, Ren X, Fang F, Li W, Zhu Y, Peng B, Wang J, Zhong Y, Cui L (2020) Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study. Neurology(R) neuroimmunology & neuroinflammation 7 (3). https://doi.org/10.1212/nxi.0000000000000705

  14. Rigal J, Ciron J, Lépine Z, Biotti D (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Multiple Scler Relat Disord 41:102019. https://doi.org/10.1016/j.msard.2020.102019

    Article  CAS  Google Scholar 

  15. Tzartos JS, Karagiorgou K, Tzanetakos D, Breza M, Evangelopoulos ME, Pelidou SH, Bakirtzis C, Nikolaidis I, Koutsis G, Notas K, Chroni E, Markakis I, Grigoriadis NC, Anagnostouli M, Orologas A, Parisis D, Karapanayiotides T, Papadimitriou D, Kostadima V, Elloul J, Xidakis I, Maris T, Zisimopoulou P, Tzartos S, Kilidireas C (2020) Deciphering anti-MOG IgG antibodies: clinical and radiological spectrum, and comparison of antibody detection assays. J Neurol Sci 410:116673. https://doi.org/10.1016/j.jns.2020.116673

    Article  CAS  PubMed  Google Scholar 

  16. Tao R, Qin C, Chen M, Yu HH, Wu LJ, Bu BT, Tian DS (2020) Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders. Int J Neurosci. https://doi.org/10.1080/00207454.2020.1720676

    Article  PubMed  Google Scholar 

  17. Pedapati R, Bhatia R, Singh N, Bali P, Gupta P, Saxena R, Dash D, Singh MB, Goyal V, Srivastava MVP (2020) Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum—a north Indian tertiary care centre experience and review of literature. J Neuroimmunol. https://doi.org/10.1016/j.jneuroim.2019.577143

    Article  PubMed  Google Scholar 

  18. Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, Fritz S, Brunet C, Pelletier J, Marignier R, Audoin B (2020) Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 87(2):256–266. https://doi.org/10.1002/ana.25648

    Article  CAS  PubMed  Google Scholar 

  19. Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I (2019) Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Multiple Scleros Relat Disord 39:101920. https://doi.org/10.1016/j.msard.2019.101920

    Article  Google Scholar 

  20. Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ (2020) Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis. Neuro Ophthalmol 44(1):1–4. https://doi.org/10.1080/01658107.2019.1607883

    Article  Google Scholar 

  21. Loos J, Pfeuffer S, Pape K, Ruck T, Luessi F, Spreer A, Zipp F, Meuth SG, Bittner S (2020) MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. https://doi.org/10.1007/s00415-020-09755-x

    Article  PubMed  PubMed Central  Google Scholar 

  22. Song H, Zhou H, Yang M, Wang J, Liu H, Sun M, Xu Q, Wei S (2019) Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol 2019:4015075. https://doi.org/10.1155/2019/4015075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ren Y, Chen X, He Q, Wang R, Lu W (2019) Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: a clinical phenomenon to be taken seriously. Front Neurol 10:1271. https://doi.org/10.3389/fneur.2019.01271

    Article  PubMed  PubMed Central  Google Scholar 

  24. Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S (2019) Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. J Neuro Ophthalmol 39(1):3–7. https://doi.org/10.1097/wno.0000000000000669

    Article  Google Scholar 

  25. Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, Nakashima I (2019) Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet’s disease. J Neuroimmunol. https://doi.org/10.1016/j.jneuroim.2019.577002

    Article  PubMed  Google Scholar 

  26. Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H (2019) Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome. Multiple Scleros Relat Disord 27:127–130. https://doi.org/10.1016/j.msard.2018.10.013

    Article  Google Scholar 

  27. Cobo-Calvo A, Sepulveda M, Rollot F, Armangue T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Sola-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflamm 16(1):134. https://doi.org/10.1186/s12974-019-1525-1

    Article  CAS  Google Scholar 

  28. Brayo P, Hartsell FL 3rd, Skeen M, Morgenlander J, Eckstein C, Shah S (2019) The clinical presentation and treatment of MOG antibody disease at a single academic center: a case series. J Neuroimmunol 337:577078. https://doi.org/10.1016/j.jneuroim.2019.577078

    Article  CAS  PubMed  Google Scholar 

  29. Bellinvia A, Pasto L, Razzolini L, Fratangelo R, Prestipino E, Fonderico M, Tudisco L, Amato MP (2019) The clinical spectrum of anti-MOG associated acquired demyelinating disorders: three case-reports. Multiple Scleros Relat Disord 33:51–54. https://doi.org/10.1016/j.msard.2019.05.006

    Article  CAS  Google Scholar 

  30. Kamada T, Miura S, Harada M, Irie A, Kikuchi S, Taniwaki T, Kurata S, Uchiyama Y, Takahashi T (2019) Bilateral cingulate cortices lesions in two autoantibodies directed against MOG (MOG-Ab)-positive patients. Multiple Scleros Relat Disord 29:108–110. https://doi.org/10.1016/j.msard.2019.01.035

    Article  Google Scholar 

  31. Biotti D, Lerebours F, Bonneville F, Ciron J, Clanet M, Brassat D (2018) Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Multiple Scleros (Houndmills, Basingstoke, England) 24(12):1645–1647. https://doi.org/10.1177/1352458518765677

    Article  Google Scholar 

  32. Gutman JM, Kupersmith M, Galetta S, Kister I (2018) Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures. J Neurol Sci 387:170–173. https://doi.org/10.1016/j.jns.2018.01.042

    Article  CAS  PubMed  Google Scholar 

  33. Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A (2018) Seizures and encephalitis in myelin oligodendrocyte glycoprotein igg disease vs aquaporin 4 IgG disease. JAMA Neurol 75(1):65–71. https://doi.org/10.1001/jamaneurol.2017.3196

    Article  PubMed  Google Scholar 

  34. Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-Associated disorders. JAMA Neurol 75(11):1355–1363. https://doi.org/10.1001/jamaneurol.2018.1814

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC, Andrews P, Barton J, Burrow J, Butzkueven H, Cairns A, Calvert S, Caruana P, Chelakkadan S, Clark D, Fraser C, Freeman J, Gill D, Grattan-Smith P, Gupta S, Hardy T, Kothur K, Ling S, Lopez J, Malone S, Marriott M, Nosadini M, O’Grady G, Orr C, Ouvrier R, Parratt J, Patrick E, Pilli D, Riminton D, Riney K, Rodriguez-Casero V, Ryan M, Scheffer I, Shah U, Shuey N, Spooner C, Subramanian G, Tea F, Thomas T, Thompson J, Troedson C, Ware T, Webster R, Yiannikas C, Yiu E, Zou A (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127–137. https://doi.org/10.1136/jnnp-2017-316880

    Article  PubMed  Google Scholar 

  36. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4(2):e322. https://doi.org/10.1212/nxi.0000000000000322

    Article  PubMed  PubMed Central  Google Scholar 

  37. Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R (2017) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Scleros (Houndmills, Basingstoke, England) 23(10):1377–1384. https://doi.org/10.1177/1352458516678474

    Article  CAS  Google Scholar 

  38. Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S (2017) Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J Neurol Sci 381:240–244. https://doi.org/10.1016/j.jns.2017.08.3254

    Article  CAS  PubMed  Google Scholar 

  39. Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N (2016) The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Multiple Scleros (Houndmills, Basingstoke, England) 22(7):964–968. https://doi.org/10.1177/1352458515614093

    Article  CAS  Google Scholar 

  40. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277. https://doi.org/10.1212/WNL.0b013e31826aac4e

    Article  CAS  PubMed  Google Scholar 

  41. Winklmeier S, Schlüter M, Spadaro M, Thaler FS, Vural A, Gerhards R, Macrini C, Mader S, Kurne A, Inan B, Karabudak R, Özbay FG, Esendagli G, Hohlfeld R, Kümpfel T, Meinl E (2019) Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm 6(6):625. https://doi.org/10.1212/nxi.0000000000000625

    Article  PubMed  PubMed Central  Google Scholar 

  42. Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stuve O (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697. https://doi.org/10.1177/1756286418761697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostasy K, Neuteboom R, Deiva K, Lim M (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75(4):478–487. https://doi.org/10.1001/jamaneurol.2017.4601

    Article  PubMed  PubMed Central  Google Scholar 

  44. Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19(5):391–401. https://doi.org/10.1016/s1474-4422(20)30070-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67(8):1016–1017. https://doi.org/10.1001/archneurol.2010.188

    Article  PubMed  Google Scholar 

  46. Juryńczyk M, Jacob A, Fujihara K, Palace J (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 19(3):187–195. https://doi.org/10.1136/practneurol-2017-001787

    Article  PubMed  Google Scholar 

Download references

Funding

This article was supported by the Peking University Health Science Center—University of Ulm Joint Center for Neuroscience fund (PKU2017ZC001-1).

Author information

Author notes

  1. Qianshuo Lu and Jingjing Luo have contributed equally to the work.

Authors and Affiliations

  1. Department of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034

    Qianshuo Lu, Jingjing Luo, Hongjun Hao, Ran Liu, Haiqiang Jin, Yunyi Jin & Feng Gao

Authors
  1. Qianshuo Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingjing Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongjun Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ran Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haiqiang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunyi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Feng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Gao.

Ethics declarations

Conflict of interest

All of the authors declare no financial or other conflicts of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, Q., Luo, J., Hao, H. et al. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol 268, 4537–4548 (2021). https://doi.org/10.1007/s00415-020-10236-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-020-10236-4

Keywords

Search

Navigation